Effect of Epitalon on biomarkers of aging, life span and spontaneous tumor incidence in female Swiss-derived SHR mice

This long-term study conducted by Anisimov's group, pioneers in regulatory peptide aging research, evaluated the effects of Epitalon (Ala-Glu-Asp-Gly) on aging biomarkers, life span, and spontaneous tumor incidence in female SHR (Swiss-derived) mice. Animals received subcutaneous injections of Epitalon in cycles of 5 days per month starting at 3 months of age.

Results demonstrated that Epitalon treatment increased mean life span by 12.3% compared to controls. Additionally, there was a significant reduction in spontaneous tumor incidence, particularly mammary adenocarcinomas, which are common in this strain. Treatment also delayed the onset of phenotypic signs of aging.

The study evaluated multiple biomarkers, including estrous (reproductive) function, body temperature, body weight, and hematological parameters. Treated animals maintained regular estrous cycles for a significantly longer period, suggesting preservation of neuroendocrine function. No significant adverse effects were observed throughout the experimental period.

These findings are particularly relevant for demonstrating that a synthetic tetrapeptide can influence both longevity and tumor suppression in an animal model, reinforcing the hypothesis that peptidic regulation of the pineal gland plays an important role in aging and carcinogenesis processes.